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The isolated islet of Langerhans as a
micro-organ and its transplantation to
cure diabetes mellitus:
Celebrating the legacy of Paul Lacy.
WUMS Historica Medica Lecture 43
February 19, 2015
Stan Misler

Paul E. Lacy, M.D., Ph.D
(1924-2005)
Late Kroc Professor Emeritus,
Department of Pathology,
Washington University Medical School

Two careers in one: “I started my career wanting
to learn about the structural basis and cell
mechanics of insulin secretion and ended it with a
mission to try to cure diabetes with islet
transplantation. Gosh, what a surprising turn a
life in science can take!”

“Grandpa Islet”

Encourager, enabler, galvanized of others
Proselytizer for islet transplantation: inspiring speaker and amazing gatherer of industrial
grant support
Asked “why not” when others more timid asked “wherefore and how”
Personal legacy of openness and generosity of spirit as a mentor may be as important
as his legacy to science

“Its time not to talk about what
we’ve done because we’re only
as good as the ideas we inspire”
What hath Paul Lacy wrought?
What followed him?

1. The islet as micro-organ

“As a pathologist, I believe what I see.”
A. Pioneering islet microscopy:
1. Characterization of a, b, d cell structure:
b-cell identified by granule depletion on
glucose and sulfonylurea stimulation and
b-cell kill off by streptozytocin
2. Conceptualization of granule
“emiocytosis” (exocytosis) for hormone
exit
3. Recognition importance of granule
maturation; roles of Ca in exocytosis &
cytoskeleton in granule movement;
preferential approach of granules to
membrane after glucose stimulation;
Dark field microscopy

B. Lacy’s Gift: isolated islet of Langerhans

12-fold peak increase

4-fold sustained decrease

Single islet cells &
Cytosolic components of
islet cells esp. hormone
containing granules

“Draw me a simple picture of what is
happening between uptake of glucose
and insulin secretion….and while
you’re at it where are the sore spots in
type 2 Diabetes (mellitus) ”

C. Consensus model of operation of insulinsecreting b cell
1. Glucose uptake by plasma membrane glucose
transporters ->
2. Oxidative metabolism of glucose, including by
mitochondria, resulting in increased cytosolic
ATP and decreased ADP ->
3. Closure of ATP sensitive K channels, KATP
against a background of open non-selective
cation channels C(NS) ->
4. Membrane depolarization ->
5. Opening of voltage dependent ion channels
including Ca channels ->
6. Ca entry with binding to protein complex
anchoring insulin granule to plasma
membrane ->
7. Fusion of insulin granule membrane with
plasma membrane and exocytotic release of
insulin granule contents. Also some release of
GABA from smaller vesicles
C(NS)

KATP

1. A potassium channel (KATP) closed by bath applied
glucose or sulfonylurea in cell attached patch of intact cell is
also closed by bath applied ATP and reopened by bath
applied ADP in the inside-out excised membrane patch
Inside-out excised patch

Cell attached
membrane
patch

Fluid stream

Inside out excised
membrane patch

Fluid stream

2. Stimulus – depolarization coupling in beta cells:
glucose metabolism -> closure of KATP channels against
background of non selective cation channels, C(NS) -> cell
depolarization -> electrical activity due to sequential opening of Na,
Ca and K channels

Perforated
patch mode
before patch
perforation

Perforated
patch mode
after patch
perforation

3. Unraveling exocytosis in single b cells
Exocytosis = incorporation of granule membrane into plasma
membrane resulting in increased membrane capacitance (prop.
surface area; measured by patch clamp mode) as well as
simultaneous release of granule’s chemical contents sensed
electrochemically (after preloading with serotonin) or seen as
emptying of fluorescent marker (total internal reflectance
fluorescence microscopy)

Fluorescent marker

Quantal release in b-cells as measured
by capacitance increase (DCm) and
amperometry (Iamp)

Single action
potentials ->
single granule
exocytosis

Prolonged
depolarization
-> release of
10s of quanta

4. Cellular basis of gut secreted incretin GLP-1
and vagus nerve secreted Ach in enhancing
glucose-induced insulin secretion:
enhanced closure of KATP and recruitment of insulin
granules for exocytosis

6. Islet paracrine or “social” interactions

b-cells at center of islet perfused first and secrete best when
electrically coupled
GABA released by b-cell contributes to depolarization-based
inactivation of a-cell
Somatostatin from d cells reduces secretion from b and a cells:
G-protein coupled receptor and stimulation of phosphodiesterase

7. Implications for Etiology of Type 2-DM
(Ashcroft & Rorsman; Nicholls)
T2DM, afflicting overweight and older persons
with hyperglycemia, has been widely attributed to
the “tune-out” of peripheral fat, muscle and liver
cells to the effect of insulin thereby promoting
hyperglycemia that was toxic to most cells.
However newer evidence suggests that b-cell
defects are important initiators of the phenotype.
(i) Mutations that provide a gain of function of
KATP (i.e., channels inherently less sensitive
to ATP-induced closure) produce T2DM.
Actual damage to b-cells can be prevented
by normalizing insulin secretion with
treatment with a sulfonylurea
(ii) Day’s long exposure to high concentrations
high free fatty acids such as palmitate results
in disordering of tight coupling of Ca
channels to insulin granules in IRP thus
reducing depolarization – induced exocytosis
(inc Cm) at unchanged calcium current

------------>more hyperglycemic

Control

2. The isolated islet for transplantation

Ricordi: Gartner innovation curve (or hype
cycle) defining steps in evolution of clinical
islet transplantation

A. Lacy’s vision of “curative” islet
transplantation in unstable Type I diabetes
• “Islet greediness”: “Harvest pancreas’ worth of islets
from a single human donor, purify them, and culture
them to reduce their antigenicity
•“Transplant islets into a safe location” in the
recipient where they would take root and provide insulin
independence, or at least eliminate the daily highs and
lows of blood sugars
•Strategies might be needed to prevent immune
attacks to avoid long-term use of immunosuppressants

B. Best guess as to Lacy’s basic
assumptions underlying islet transplantation
(i) Reduced model of islet function
• b-cell-centricity: Need for moment-to-moment function of
beta cells to secrete insulin to control blood glucose
Hyperglycemic function of a-cells secondary concern and
should be maintained as in perifusions
Post Lacy: Restoration of C peptide secretion -> decreased
neuropathy and increased myocardial and renal blood flow)
• Innervation and incretins not essential: glucose-induced
biphasic secretion seen in isolated, cultured islets. However,
incretins (e.g., synthetic analogs of GLP-1) might be used to
enhance islet function in marginal cases
• Islet cells poorly antigenic and if well treated may not
need long term immunosuppression: limited antigenicity
arises from passenger immune cells and endothelium
• Islet cells intrinsically plastic: hypertrophy and
replacement of worn-out cells occurs in intact islets

(ii) Ease of islet transplantation as compared

with whole pancreas transplantation
• Many choices of target sites: subcapsular in kidney or
spleen; intraperitoneal; but especially intrahepatic via
injection/embolization into portal vein to provide first
pass source of insulin for hepatocytes
• Whole pancreas Tx complicated by high M/M
• No need for exocrine drainage.

C. Proof of principle
(Ballinger, Scharp and Lacy, 1973)
Syngeneic islet transplantation: 400-600 islets into
portal veins of streptozotocin-treated, single dose
immunosuppressed rats ->
2-12 weeks: abolition of polydypsia, polyuria and postprandial hyperglycemia; establishment of near normal
resting glucose and insulin levels; and reversal of
histological lesions of mesenteric autonomic nerve
supply
5 months: well granulated intrahepatic beta and alpha
cells forming direct contacts with hepatocytes

D. “Trigger technology” = high yield isolation of
islets from pancreati of large mammals

Collagenase
digestion of
pancreas helped by
marbles pounding
whole pancreas

E. Clinical islet transplantation at the “peak
of inflated expectations” beginning in 1990

1. Procedure: Isolation of
islets from pancreata
and infusion into liver via
percutaneous transhepatic
catheterization of portal
vein under fluoroscopic or
ultrasound guidance

Portogram of
injection

Courtesy: D. Brennan, WUMC

MRI showing
engraftment
(steatosis =
local fatty liver)

2. First 15 years of trials, the best results ->
“trough of disillusionment” 2005

• Edmonton + Miami + Minnesota
• Type 1 DM X 25 years; hypoglycemic episodes but no renal dysfunction
• Semi-selected pancreati (ABO but not HLA compatible donors without history
of DM); cold ischemia < 12h
• Initial transplant 400,000 islet equivalents (IE) (5 cc), 0-2 boosters -> average
total 800,000 IE; later 10,000 -14,000 IE /kg body weight
• Induction with antiCD25 antibody (later strong lymphodepleting induction) and
steroid free immunosuppression with low dose calcineurin inhibitor and high
dose mTOR inhibitor; more recently conversion to mycophenolate acid to
avoid nephrotoxicity
• 82% insulin dependent at 1 yr; 20% at 5 years (82% graft survival by C-pep)
• Better glycemic control (HbA1c 7 vs. 9) with fewer episodes of hypoglycemia
even if not insulin-dependent after transplant of “marginal” tissue
• Chronic complications: mouth ulcers, anemia, diarrhea, ovarian cysts, acne,
increased need for antihypertensives, statins
• Unsolved: peripheral/autonomic neuropathy; hypoglycemic counterregulation/awareness

F. Overcoming the myopia in early transplant
vision or “the slope of enlightenment”
Initially little intimate knowledge or standardization of the
islet as a micro-organ.
(a) A priori, metabolic state of transplanted islets should determine
their long-term survival and should be dependent on: (i) condition of
source pancreas and islets and (ii) stability of islets as micro-organ
out of their pancreatic milieu
(b) However there was continued reliance on pre-transplant
optical measures of immediate “viability”, “gentle standards” for
quantitation of yield (what is an IE?) and for “in vitro” secretion
after acute culture (2-3 fold increase).
Little or no extensive post-transplant assays of “in vivo”
functional reserve (e.g., C peptide secretion)

G. Complex pre-transplant issues:
Dependence on source and early treatment
(a) Pre-harvest of pancreas: donor age, adiposity, insulin reserve,
& cytokine storm in brainstem death
Conundrum: islets of lean & <35y/o -> difficult to liberate but likely robust islets
vs. islets of obese & > 50 -> large, encapsulated, easy to liberate islets
with less function

(b) Post-harvest of pancreas and pre-isolation of islets: cold
ischemia time usually > optimum 6-8 h (“left-over organs”);
fluorocarbon O2 transport solution
(c) Continuing problems of isolation: enzyme potency and
exposure time
(d) Post-isolation: shaggy vs. round; fresh vs. cultured
(e) Newer developments for rapid pre-transplant islet screening:
Laser scanning cytometry; mitochondrial membrane potential
assay; tests of increased O2 consumption with glucose
stimulation

H. Complex post-transplant issues:
1. “Stranger in a strange hepatic land”-> acute
and chronic loss of tissue and function
Islet transplants into liver
survive less well than those
infused into pancreas:
(i) decreased glucose oxidation
and insulin secretion;
(ii) down-regulation of
expression of genes of
differentiation;
(iii) reduced probability of islet
cell replacement by local stem
cells and budding pancreatic
ducts

2. Attacking islet ischemia and poor posttransplant proliferation
(a) 30% of islets have necrotic cores at time of infusion -> need for
non-ischemic preparation
(b) Loss of 30-40% of viable islets by “hypoxia-reperfusion injury”
-> ischemia Inhibitable by nicotinamide
(c) Rapid onset of apoptosis (including lymphocyte induced) + a, b ->
loss of 80% of islets in 3 days.
Inhibition by ex vivo transduction of islets with X-linked inhibitor
of apoptosis ?
(d) Poor acute and long-term functional revascularization and
oxygenation
Intra-islet pO2 = 5-10 torr vs. 40 torr in situ -> switch to anerobic
respiration with poor stimulus-evoked secretion. No current treatment
(e) Poor islet cell proliferation Improved by transduction of
proliferation switch -> activation of Jak-Stat pathway by
membrane permeant agonists?

I. Success with alternative transplantation
modalities: lessons learned
•

•

Freshly prepared, partially purified pancreatic tissue
infused into portal vein results in long-term (up to 13
year) reduction in fasting glucose and HBA1c; correlated
with mass of infused tissue.
Implies that mass of co-transplanted acinar and ductal
tissue not an impediment
Solitary pancreatic transplantation or simultaneous with
renal transplantation results in 70-80% survival of
pancreatic function up to 3 years (Improvement due to
reduced exocrine damage during harvest; bladder drainage
of ductal secretion; tacrolimus-based immunosuppression).
Implies that immunosuppression is not a swift and potent
islet killer

J. The future
1. Finding a better microenvironment for islet
transplantation: the bone marrow?
“Who would have thunk it ?”

2. Human islet transplantation likely to be superseded
by a bioengineering approach…. but which?
• Chemical engineering of encapsulation with alginate: xenogenic
porcine microencapsulation followed by (i) intraperitoneal injection or
(ii) macro or hollow fiber encapsulation with subcutaneous patch
implantation. This should avoid immunosuppression and in
xenotransplant should protect against foreign oncogenes, viruses
while still susceptible to macrophage attack.
• Developmental engineering: induction of embryonic stem cells (ES
= inner cell mass of preimplantation blastocysts) or pleuripotential
stem cells (iPS) for differentiation along b-cell lineage
• Cell engineering (transdifferentiation): directed transdifferentiation
of hepatic and pancreatic exocrine ductal cells or acinar cell line
reprogramming of these by adenovirus mediated transduction of
PDX1 and NGN3, MAFA for ectopic expression
• Whole organ bioengineering: pancreatic extracellular matrix (ECM)
with signaling molecules and growth factors to drive cellular
repopulation, and enhance islet secretion and survival. Mimicable by
biomolecular carriers?
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